strap yaself in, page-5

Could this have contributed;

Sydney - Wednesday - October 14: (RWE Aust Business News) - CSL
Ltd (ASX:CSL) is trading consistent with expectations, the chairman said
today.
"At the time of announcing our full year's result in August, we
indicated an expectation of continuing growth in the demand for plasma
therapies with sales benefiting from a product mix change with a shift
towards Privigen," Elizabeth Alexander told shareholders at the annual
general meeting.
"Following the successful roll out of the human papillomavirus
vaccine program in Australia, sales of GARDASIL are expected to decline
substantially with the catch-up program drawing to a close.
"However, the novel H1N1 influenza vaccine is expected to provide
a strong contribution this year.
"For the 2009/2010 fiscal year, we expect net profit after tax to
be between $1.16 billion and $1.26 billion at 2008/2009 exchange rates.
"However, if currency rates on 9 October 2009 were to apply for
the balance of the fiscal year, the net profit after tax range referred
to earlier would be in the order of $970 million to $1.070 billion."